Mitochondrial DNA depletion in HIV-infected patients is more pronounced with chronic hepatitis C and enhanced following treatment with pegylated interferon plus ribavirin

Antiviral Therapy

Volumn 10, Issue 4, 2005, Pages 557-561

  De Mendoza, Carmen ^a   Sánchez Conde, Matilde ^a   Timmermans, Eveline ^b   Buitelaar, Marije ^b   De Boor, Michel P ^b   Gonzalez Lahoz, Juan ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Primagen   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; MITOCHONDRIAL DNA; PEGINTERFERON; RIBAVIRIN;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; MITOCHONDRIAL DNA DEPLETION; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RISK FACTOR;

ADULT; ANTIVIRAL AGENTS; DNA, MITOCHONDRIAL; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERONS; MALE; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 23044517082     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Brinkman K, ter Hofstede H & Burger D. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as a common pathway. AIDS 1998; 12:1735-1744.
2. Walker U, Setzer B & Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogues reverse transcriptase inhibitors. AIDS 2002; 16:2165-2173.
3. Dagan T, Sable C & Bray J. Mitochondrial dysfunction and antiretroviral nucleoside analogues toxicities: what is the evidence? Mitochondrion 2002; 1:397-412.
4. Cote H, Zabrina D & Brumme L. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV infected patients. New England Journal of Medicine 2002; 346:811-820.
5. De Mendoza C, de Ronde A, Smolders K & Soriano V. Changes in mitochondrial DNA copy number in blood cells from HIV-infected patients undergoing antiretroviral therapy. AIDS Research & Human Retroviruses 2004; 20:271-273.
6. Miura T, Goto M & Hosoya N. Depletion of mitochondrial DNA in HIV-1 infected patients and its amelioration by antiretroviral therapy. Journal of Medical Virology 2003; 70:497-505.
7. Zylberberg H, Nalpas B & Pol S. Is there a relationship between hepatitis C virus infection and antiretroviral-associated lipoatrophy? AIDS 2000; 14:2055.
8. Lafeuillade A, Hittinger G & Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357:280-281.
9. Garcia-Benayas T, Blanco F & Soriano V. Weight loss in HIV-infected patients. New England Journal of Medicine 2002; 347:1287-1288.
10. De Mendoza C, Sánchez-Conde M, Rivera E, Domingo P & Soriano V. Could mitochondrial DNA quantitation be a surrogate marker for drug mitochondrial toxicity? AIDS Reviews 2004; 6:169-180.
11. van der Valk M, Casula M, Weverling G, van Kuijk K, van Eck-Smit B, Hulsebosch H, Nieuwkerk P, van Eeden A, Brinkman K, Lange J, de Ronde A & Reiss P. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy. Antiviral Therapy 2004; 9:385-393.
12. Soriano V, Puoti M, Sulkowski M, Cargnel A, Dietrich D & Rockstroh J. Care of patients with hepatitis C and HIV co-infection. Updated recommendations from the HIV-HCV International Panel. AIDS 2004; 18:1-12.
13. Bauerle J, Laguno M, Mauss S, Mallolas J, Murillas J, Miquel R, Schmutz G, Setzer B, Gatell JM & Walker U. Mitochondrial DNA depletion in liver tissue of patients infected with hepatitis C virus: contributing effect of HIV infection? HIV Medicine 2005; 6:135-139.
14. Barbaro G, Di Eorenzo G & Asti A. Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: ultrastructural and biochemical findings. American Journal of Gastroenterology 1999; 94:2198-2205.
15. Okuda M, Li K & Beard M. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122:366-375.
16. De Maria N, Colantoni A & Fagiuoli S. Association between reactive oxygen species and disease activity in chronic hepatitis C. Free Radical Biology & Medicine 1996; 21:291-295.
17. Hayashi N & Mita E. Fas system and apoptosis in viral hepatitis. Journal of Gastroenterology & Hepatology 1997; 12:223-226.
18. Prikhod'ko E, Prikhod'ko G & Siegel R. The NS3 protein of hepatitis C virus induces caspase-8-mediated apoptosis independent of its protease or helicase activities. Virology 2004; 329:53-67.
19. Bantel H, Lugering A & Heidemann J. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 2004; 40:1078-1087.
20. Feldstein A & Gores G. An apoptotic biomarker goes to the HCV clinic. Hepatology 2004; 40:1044-1046.
21. Guseva N, Taghiyev A, Sturm M, Rokhlin O & Cohen M. Tumor necrosis factor-related apoptosis inducing ligand-mediated activation of mitochondria-associated factor-kappaB in prostatic carcinoma cell lines. Molecular Cancer Research 2004; 10:574-584.
22. Maher B, Lloyd J, Wilkins E, Eraser W, Back D, Park B & Pirmohamed M. Lipodystrophy in patient with HIV-1 infection: effect of stopping protease inhibitors on TNF-alpha and TNF-receptor levels, and on metabolic parameters. Antiviral Therapy 2004; 9:879-887.
23. Fried M, Shiffman M & Reddy R. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine 2002; 347:975-982.
24. Torriani F, Rodriguez-Torres M &c Rockstroh J; on behalf of the APRICOT trial. Peginterferon alfa 2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. New England Journal of Medicine 2004; 351:438-450.
25. Carrat F, Bani-Sadr F, Pol S, on behalf of the RIBAVIC trial. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. Journal of the American Medical Association 2004; 292:2909-2913.
26. Moreno A, Quereda C, Moreno L & Moreno S. High rate of didanosine-related mitochondrial toxicity in HIV/HCV coinfected patients receiving ribavirin. Antiviral Therapy 2004; 9:133-138.
27. Mauss S, Valenti W, De Pamphilis J, Duff F, Cupelli L, Passe S, Solsky J, Torriani F, Dieterich D & Larrey D. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004; 18:F21-F25.
28. Walker U, Bauerle J, Laguno M, Mallolas J & Gatell J. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 2004; 39:311-317.